ContraFect Corporation [NASDAQ: CFRX] loss -1.26% on the last trading session, reaching $1.18 price per share at the time. The company report on April 6, 2023 that ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting.
Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
ContraFect Corporation represents 0.49 million in outstanding shares, while the company has a total market value of $1.68 million with the latest information. CFRX stock price has been found in the range of $1.12 to $1.23.
If compared to the average trading volume of 684.98K shares, CFRX reached a trading volume of 154167 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about ContraFect Corporation [CFRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CFRX shares is $400.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CFRX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
SVB Leerink have made an estimate for ContraFect Corporation shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on July 14, 2022. While these analysts kept the previous recommendation, Cantor Fitzgerald dropped their target price from $15 to $1. The new note on the price target was released on July 14, 2022, representing the official price target for ContraFect Corporation stock. Previously, the target price had yet another raise to $6.50, while WBB Securities analysts kept a Buy rating on CFRX stock.
Trading performance analysis for CFRX stock
ContraFect Corporation [CFRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -46.12. With this latest performance, CFRX shares dropped by -53.91% in over the last four-week period, additionally sinking by -91.81% over the last 6 months – not to mention a drop of -99.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CFRX stock in for the last two-week period is set at 26.46, with the RSI for the last a single of trading hit 20.99, and the three-weeks RSI is set at 29.55 for ContraFect Corporation [CFRX]. The present Moving Average for the last 50 days of trading for this stock 3.3759, while it was recorded at 1.4580 for the last single week of trading, and 29.7851 for the last 200 days.
ContraFect Corporation [CFRX]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -347.26, with Return on Assets sitting at -149.02.
ContraFect Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.80.
ContraFect Corporation [CFRX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CFRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ContraFect Corporation go to 12.70%.
An analysis of insider ownership at ContraFect Corporation [CFRX]
There are presently around $0 million, or 22.80% of CFRX stock, in the hands of institutional investors. The top three institutional holders of CFRX stocks are: ARMISTICE CAPITAL, LLC with ownership of 51,189, which is approximately New of the company’s market cap and around 2.05% of the total institutional ownership; ACADIAN ASSET MANAGEMENT LLC, holding 19,860 shares of the stock with an approximate value of $24000.0 in CFRX stocks shares; and ARTAL GROUP S.A., currently with $22000.0 in CFRX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in ContraFect Corporation stocks held by institutional investors increased at the end of Friday and at the time of the Friday reporting period, where 12 institutional holders increased their position in ContraFect Corporation [NASDAQ:CFRX] by around 61,725 shares. Additionally, 25 investors decreased positions by around 31,694 shares, while 16 investors held positions by with 48,557 shares. The mentioned changes placed institutional holdings at 141,976 shares, according to the latest SEC report filing. CFRX stock had 6 new institutional investments in for a total of 53,639 shares, while 12 institutional investors sold positions of 19,778 shares during the same period.